Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.12 Billion KRW | 14.52% |
| 2022 | -10.02 Billion KRW | -28.27% |
| 2021 | -7.81 Billion KRW | 14.35% |
| 2020 | -9.12 Billion KRW | -352.46% |
| 2019 | -2.01 Billion KRW | -203.87% |
| 2018 | 1.94 Billion KRW | -15.61% |
| 2017 | 2.3 Billion KRW | -61.87% |
| 2016 | 6.03 Billion KRW | -10.8% |
| 2015 | 6.76 Billion KRW | 0.0% |
| 2013 | 5.17 Billion KRW | 70.9% |
| 2012 | 3.02 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -644.19 Million KRW | 75.3% |
| 2024 Q2 | -774.74 Million KRW | 93.8% |
| 2023 Q4 | -2.6 Billion KRW | -29.98% |
| 2023 FY | -8.57 Billion KRW | 14.52% |
| 2023 Q1 | -1.95 Billion KRW | 19.95% |
| 2023 Q2 | -2.1 Billion KRW | -7.34% |
| 2023 Q3 | -2 Billion KRW | 4.62% |
| 2022 FY | -10.02 Billion KRW | -28.27% |
| 2022 Q2 | -2.31 Billion KRW | -43.28% |
| 2022 Q3 | -2.99 Billion KRW | -29.32% |
| 2022 Q1 | -1.61 Billion KRW | 61.72% |
| 2022 Q4 | -2.44 Billion KRW | 18.31% |
| 2021 Q3 | 307.85 Million KRW | 114.9% |
| 2021 Q4 | -4.22 Billion KRW | -1472.55% |
| 2021 FY | -7.81 Billion KRW | 14.35% |
| 2021 Q2 | -2.06 Billion KRW | -12.67% |
| 2021 Q1 | -1.83 Billion KRW | -409.07% |
| 2020 FY | -9.12 Billion KRW | -352.46% |
| 2020 Q1 | 524.32 Million KRW | -57.93% |
| 2020 Q2 | 156.21 Million KRW | -70.21% |
| 2020 Q3 | 729.25 Million KRW | 366.84% |
| 2020 Q4 | 593.39 Million KRW | -18.63% |
| 2019 Q2 | 188.67 Million KRW | 126.09% |
| 2019 FY | -2.01 Billion KRW | -203.87% |
| 2019 Q1 | -723.3 Million KRW | -303.53% |
| 2019 Q4 | 1.24 Billion KRW | 150.95% |
| 2019 Q3 | -2.44 Billion KRW | -1396.36% |
| 2018 FY | 1.94 Billion KRW | -15.61% |
| 2018 Q3 | 596.9 Million KRW | -26.37% |
| 2018 Q4 | -179.24 Million KRW | -130.03% |
| 2018 Q2 | 810.67 Million KRW | 214.64% |
| 2018 Q1 | 257.64 Million KRW | -65.86% |
| 2017 Q3 | 706.99 Million KRW | -10.78% |
| 2017 FY | 2.3 Billion KRW | -61.87% |
| 2017 Q2 | 792.42 Million KRW | 163.35% |
| 2017 Q1 | 300.89 Million KRW | 0.0% |
| 2017 Q4 | 754.58 Million KRW | 6.73% |
| 2016 FY | 6.03 Billion KRW | -10.8% |
| 2015 FY | 6.76 Billion KRW | 0.0% |
| 2014 Q1 | 385.36 Million KRW | -82.36% |
| 2014 Q3 | 842.76 Million KRW | -27.7% |
| 2014 Q2 | 1.16 Billion KRW | 202.49% |
| 2013 FY | 5.17 Billion KRW | 70.9% |
| 2013 Q3 | 1.15 Billion KRW | 0.62% |
| 2013 Q2 | 1.14 Billion KRW | 66.24% |
| 2013 Q1 | 690.14 Million KRW | 88.98% |
| 2013 Q4 | 2.18 Billion KRW | 89.29% |
| 2012 FY | 3.02 Billion KRW | 0.0% |
| 2012 Q4 | 365.19 Million KRW | -76.61% |
| 2012 Q3 | 1.56 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 135.291% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 53.477% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 96.255% |
| Bioneer Corporation | 199.25 Billion KRW | 98.935% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | 4.138% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 94.72% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -45.631% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 99.169% |
| Medy-Tox Inc. | 128.16 Billion KRW | 98.344% |
| Peptron, Inc. | 1.14 Billion KRW | -86.033% |
| Amicogen, Inc. | 51.51 Billion KRW | 95.881% |
| Genexine, Inc. | 387.48 Million KRW | -447.596% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 68.303% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 88.078% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 93.199% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 98.836% |
| SillaJen, Inc. | 1.45 Billion KRW | -45.657% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 92.018% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 85.288% |
| Genomictree Inc. | -1.03 Billion KRW | 304.3% |
| MedPacto, Inc. | -1.83 Billion KRW | 215.78% |
| D&D Pharmatech | 18.67 Billion KRW | 88.639% |
| EASY BIO,Inc. | 50.88 Billion KRW | 95.83% |
| GI Innovation, Inc. | 1.98 Billion KRW | -6.657% |